| INTRODUCTION
Traditionally, acute kidney injury (AKI) and chronic kidney disease (CKD) are viewed as 2 distinct forms of kidney disease. 1 Acute kidney injury typically results in a rapid decrease in kidney function that may be reversible, whereas CKD usually features a slower, irreversible loss of kidney function that develops over months or longer. 1 Maladaptation and failure of regenerative repair during and after active injury in AKI and CKD may lead to loss of nephrons and development or progression of CKD. 1 However, a subset of dogs with CKD has slow or no progression over extended periods of time (stable CKD), which may reflect either a low level of ongoing injury or a combination of ongoing injury with adaptive hyperfiltration, minimizing overall loss of glomerular filtration rate (GFR). [1] [2] [3] If sufficient adaptive hyperfiltration develops, a progressive decrease in kidney function may be difficult or impossible to recognize. [1] [2] [3] Abbreviations: AKI, acute kidney injury; AUC, area under the curve; CI, confidence interval; CKD, chronic kidney disease; GFR, glomerular filtration rate; MAT, microscopic agglutination test; NGAL, neutrophil gelatinase-associated lipocalin; ROC, receiver operator characteristic; UNCR, urinary NGAL to creatinine ratio; uNGAL, urinary neutrophil gelatinase-associated lipocalin; USG, urine specific gravity.
To date, the timely identification of dogs with higher risk of CKD progression has been limited because of a lack of early diagnostic predictors. Such ability to discriminate progressive from stable CKD patients would allow clinicians to focus on treatments that slow down loss of nephrons and kidney function. Conventional kidney markers (eg, serum creatinine and symmetric dimethylarginine concentrations)
can detect progressive loss of kidney function by serial monitoring.
The limitation of this approach is that recognition occurs after loss of function has already occurred.
Tubular injury biomarkers detect ongoing active renal injury in CKD and therefore may predict the likelihood of progression of CKD before conventional functional markers. Among these is neutrophil gelatinase-associated lipocalin (NGAL), a 25-kD protein covalently bound to matrix metalloprotein-9 in neutrophils. 4 It is synthesized in low concentrations in renal tubular, intestinal, hepatic, and pulmonary tissue, but its synthesis is substantially upregulated with tissue injury. 4, 5 Circulating NGAL is filtered by the glomerulus, reabsorbed in the proximal tubule, and secreted by the thick ascending limb of the loop of
Henle. 4, 6 The urinary NGAL (uNGAL) concentration is very low under normal physiologic conditions. In active renal tubular injury, NGAL synthesis is increased, reabsorption is decreased, and secretion is increased, resulting in increased uNGAL concentrations. 6 It has been recognized as 1 of the earliest and most strongly induced proteins in both ischemic and nephrotoxic animal models of AKI. 5 Several studies in human and veterinary medicine indicate that serum NGAL and uNGAL concentrations are increased in AKI earlier than is serum creatinine concentration.
We hypothesized that dogs with progressive CKD would have urinary NGAL to creatinine ratio (UNCR) higher than dogs with stable CKD. Our objective was to determine if UNCR can differentiate between stable and progressive CKD. Recognizing increased risk of progression could prompt enhanced diagnostic, monitoring, and therapeutic approaches with the goal of decreasing nephron injury and progression of CKD. A secondary aim was to compare UNCR in the CKD groups to dogs with prerenal azotemia and AKI, and with healthy dogs. 
| MATERIALS AND METHODS

| Case dogs and group categorization
| Healthy control dogs
Twenty healthy dogs presented for routine examination to the Primary Care Service at the Veterinary Medical Center or owned by staff members were recruited. Dogs were considered to be healthy and free of prerenal or renal azotemia based on history, physical examination findings, CBC, serum biochemistry profile, urinalysis, and urine culture.
| Sample collection
Remaining urine supernatant was obtained after urinalysis and used for uNGAL and urine protein to creatinine ratio (UPC) quantification.
Urine was included if it was collected from dogs by voiding or cystocentesis at presentation (all groups) or within 36 hours of presentation for hospitalized dogs (Groups 3 and 4). In validation studies, uNGAL was stable in urine stored at 4 C up to 7 days and at −80 C up to 11 months and repeated freeze-thaw procedures did not affect NGAL measurement. 7, 8 For dogs with prerenal azotemia or stable CKD, urine was accepted only if it was collected before fluid therapy. All urine samples were stored at −80 C pending NGAL determination. Complete blood count, serum biochemistry profile, urinalysis, and follow-up serum biochemistry were performed at the laboratory of the Veterinary Medical Center of the University of Minnesota. Urine culture and susceptibility testing were performed at an outside reference laboratory (Marshfield Labs, Marshfield, Wisconsin).
| NGAL ELISA and UNCR
One urine sample, collected at presentation or within up to 36 hours of presentation, was used for a single uNGAL measurement and UNCR calculation for all dogs. Urinary NGAL concentrations were measured by a commercially available sandwich ELISA kit (BioPorto, Denmark) according to the manufacturer's instructions, and optic density was measured at 450 nm using an ELISA plate reader (FluorChemHD2; Alpha Innotech, San Leandro, CA). A standard curve for NGAL was created using 8 dilutions (ranging from 0 to 400 pg/mL) of canine NGAL reference standard provided with the assay. The limits of the NGAL ELISA were 0-400 pg/mL. All samples in which NGAL measurements were above the upper limit of detection were diluted and run in duplicate. The highest dilution required to was 1 : 1200. The urinary NGAL concentrations (pg/mL) were calculated from a 4-parameter nonlinear standard curve created using curve fitting software (Optima; BMG Labtech, Cary, NC).
Urine creatinine concentrations (mg/dL) were measured in the laboratory of the Veterinary Medical Center using standard techniques by an automatic analyzer. The UNCR (in pg/mg) were calculated as (urine NGAL)/(urine creatinine).
| Proteinuria
Proteinuria was defined as a UPC > 0.5 when UPC data were available or urine protein ≥1+ on the sulfosalicylic acid turbidity test when UPC data were not available. All dogs with proteinuria had inactive sediment (no hematuria, pyuria, or bacteriuria). All dogs with positive urine cultures were excluded from the study.
| Urine protein : creatinine ratio
Although not an initial aim of the study, after analysis of UNCR between CKD groups, we elected to evaluate UPC in dogs with stable and progressive CKD to determine if this information was helpful in differentiating between these 2 groups. Urine protein concentrations were measured in a single urine sample in the laboratory of the Veterinary Medical Center using standard techniques by an automatic analyzer (AU480; Beckman Coulter, Brea, CA). The UPC ratios were calculated as (urine protein)/(urine creatinine).
| Statistical analysis
To test for differences between clinical groups, pairwise Wilcoxon rank sum tests were used for continuous variables (creatinine, UNCR, UPC) and pairwise proportion tests were used for binary variables (proteinuria).
When >2 groups were compared, P-values were corrected for multiple comparisons using the Bonferroni-Holm adjustment. Additionally, to test for an association of serum creatinine concentration and UPC with UNCR, Pearson's correlation was used (with UNCR and UPC on the log scale), both for all dogs together and for each clinical group separately.
To explore the power of UNCR and UPC for predicting stable or progressive CKD status, receiver operator characteristic (ROC) curves were plotted, and the area under the curve (AUC) reported, along with sensitivity and specificity at the threshold that maximized the sum of sensitivity and specificity (Youden's index). Additionally, these data were subjected to multiple logistic regression, and the standardized odds ratios and confidence interval (CI) reported. Finally, to test for differences in signalment, the pairwise Wilcoxon test was used for age, and a chisquared test was used for sex.
| RESULTS
One hundred nineteen dogs were included in the study: 21 healthy The UNCR results for all groups are presented in Figure 3 . The median UNCR of healthy control dogs was 499 pg/mg (range, 123-24 913 pg/mg), which was significantly lower than that of all other study groups (P < .05 for prerenal azotemia, P < .0001 for the other study groups). Dogs with progressive CKD had the highest median UNCR (131 061 pg/mg), which was significantly higher than that of the stable CKD (33 287 pg/mg, P < .001) and prerenal azotemia (9025 pg/mg, Stable CKD Progressive CKD Group UPC Number FIGURE 4 Urine protein : creatinine ratio (UPC) in stable and progressive chronic kidney disease (CKD) groups. The UPC value was significantly different between stable and progressive CKD groups (P = .02). The median UPC value was 1.30 for the progressive group and 0.40 for the stable group. UPC, urine protein : creatinine ratio P < .0001) groups; no significant difference in UNCR was found between the prerenal and stable CKD groups (P = .07). Although AKI had the second highest median UNCR (125 781 pg/mg), because of a wide range within that group, there was not a statistically significant difference with either the progressive CKD (P = .56) or stable CKD groups (P = .07), only the prerenal azotemia group (P < .001). Serum creatinine concentration was significantly correlated with UNCR when evaluating the entire cohort, ignoring the groups, (r = 0.70, P < .0001) and across the 2 CKD groups (r = 0.50, P = .0003). However, when the correlation between serum creatinine con- Figure 6A ). Using a UNCR threshold of 88 600 pg/mg, UNCR was able to distinguish between progressive and stable CKD with a sensitivity of 0.800 and specificity of 0.789. In contrast, the ROC using UPC as a predictor for progressive CKD had an AUC of 0.696 (95% CI, 0.529-0.863), resulting in a sensitivity of 0.828 but a specificity of 0.579 when the optimal threshold UPC of 0.45 was used ( Figure 6B ). In a multiple logistic regression model, using log(UNCR) and log(UPC) to predict progressive CKD, UNCR was significant (P = .005), but UPC was not (P = .35). For a 1 SD increase in log(UNCR), the odds of a dog having progressive CKD increase by FIGURE 6 Receiver operator characteristic curve for differentiating dogs with progressive chronic kidney disease (CKD) from dogs with stable CKD based on a urinary neutrophil gelatinase-associated lipocalin to creatinine ratio (A) and urine protein : creatinine ratio (B). Area under the curve (AUC) of urine NGAL/creatinine ratio (UNCR) is 0.816; AUC of UPC is 0.696. UPC, urine protein : creatinine ratio Urinary NGAL and UNCR have been shown to be sensitive markers for induced or naturally occurring AKI in dogs, and increases have been detected substantially earlier than those of serum creatinine concentration in dogs with AKI. 5, [9] [10] [11] [12] [13] [14] The UNCR also was significantly increased in dogs and cats with naturally occurring CKD compared to healthy controls or dogs with lower urinary tract disease. 15 In our study, we categorized dogs with CKD into 2 separate groups, progressive CKD and stable CKD, and a significant difference in UNCR was found in those Active kidney injury, which is reflected by an increase in tubular injury biomarkers such as NGAL, may play an important role in CKD progression.
A limitation of our study is the limited number of dogs with serum creatinine concentration between 2.5 and 4 mg/dL. Ultimately, a larger cohort of dogs with CKD across a spectrum of serum creatinine concentrations is needed to determine if UNCR can predict CKD progression at early IRIS stages.
Proteinuria is recognized as a robust risk factor for progression to end-stage CKD in humans as well as progression of kidney disease in dogs and cats. 3 Proteinuria may promote CKD progression by increased toxicity to the renal tubules and mesangium and induction of a proinflammatory cascade. 3 A recent study in humans showed that renal tubular injury biomarkers including NGAL did not improve prediction of progression to end-stage renal disease beyond serum creatinine concentration or albuminuria. 16 However, their prediction models focused on detection of patients with end-stage kidney disease who required renal dialysis, whereas our progressive CKD group included dogs with a wide range of established CKD and IRIS stages that advance inevitably over time but not necessarily to end stage. The median UPC of dogs in our study with progressive CKD was significantly higher than that of those with stable CKD. However, in a multiple logistic regression model using both UNCR and UPC to differentiate progressive CKD from stable CKD, UNCR was a significant predictor but UPC was not. Additionally, the AUC of UPC differentiating the 2 groups was lower than that of UNCR. These findings suggest that UNCR can provide useful information in predicting CKD progression beyond UPC. We also hypothesize that episodes of active kidney injury might be an important risk factor for CKD progression in dogs, and tubular injury biomarkers may be useful in subsets of dogs with CKD that remain relatively free of proteinuria.
Our study's findings suggest that a continuum may exist between AKI and CKD, wherein these conditions are similar in their origins and responses to kidney injury but dissimilar in their rate of decrease in kidney function. As expected, the lowest UNCR was seen in the normal control group, followed by the prerenal azotemia group and then stable CKD, with the highest UNCR observed in the AKI and progressive CKD groups. The UNCR in dogs with AKI did not significantly differ from that of dogs with progressive CKD. Surprisingly, no significant difference was found between the AKI group and the stable CKD group, whereas a previous study found a significant difference in UNCR between those groups. 5 The lack of statistical difference between the stable CKD group and the AKI group might be explained if the AKI group dogs were sampled at a time different from when their peak active renal injury occurred. We designed our study to simulate the most common clinical settings in veterinary medicine to evaluate the utility of UNCR in such settings. Thus, at the time of sampling, almost all dogs with AKI in our study already had established azotemia with unknown durations of time from the onset of azotemia. In gentamicin-induced AKI, peak uNGAL occurred 19 days after initial renal insult (after a steep increase after day 7). 13 Therefore, we hypothesize that UNCR in our AKI group could have been underestimated by missing the optimal time for detecting the highest urinary NGAL in the midst of active ongoing renal injury.
One limitation of our study is that no clear definition for dogs with progressive CKD exists, and thus we grouped dogs based on changes in serum creatinine concentration over time, because doing so was the only way to assess whether the dogs' status was changing.
Another related limitation was that the time between serum creatinine concentration measurements was not standardized in this pilot study using convenience sampling. Some dogs might have been misclassified because repeated GFR assessment was not available. Another limitation of our study is that a single UNCR was measured but higher UNCR results could occur with progression. These findings justify a study with multiple UNCR determinations over time to confirm the value of increased UNCR in predicting progression of CKD.
In conclusion, UNCR may be a promising predictor of progression in CKD. It may provide meaningful information regarding the clinical course of CKD. Knowledge that a patient with CKD is likely to progress should prompt the clinician to increase monitoring and adjust treatment as compared to dogs with stable CKD.
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